+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020

  • ID: 3007190
  • Report
  • Region: Global
  • 170 pages
  • Allied Analytics LLP
1 of 5
The DNA diagnostics market is to grow at a CAGR of 9.8% during the analysis period

FEATURED COMPANIES

  • Abbott laboratories
  • Bayer Diagnostic
  • Bio-Rad Laboratories
  • Cephide
  • Gene-probe Inc.
  • Illumina
  • MORE
DNA diagnostics is a cutting edge method which is set to revolutionize the field of medical diagnostics. This technique enables medical professionals to identify various diseases, such as cancer, infectious diseases, and myogenic disorders, and to determine the appropriate treatment for the same. It is also used for clinical diagnostic confirmation and in prenatal diagnostics. The concept of DNA diagnostics has evolved via the breakthrough human genome project that resulted in the discovery of various disease-causing agents. The DNA diagnostics market is expected to generate 19 billion by 2020. Technological development has played a major role in improving DNA diagnostic platforms and techniques.

Some of the significant technologies which incorporate DNA diagnostics include polymerase chain reaction (PCR), microarray techniques, sequencing technology and mass spectrometry; these technologies are used for sample preparation, DNA isolation etc. Technological developments, which have led to improvements in these methodologies, drive the growth of the DNA diagnostics market. The use of DNA diagnostic methods in prenatal diagnostics and clinical confirmation has also boosted market growth. The DNA diagnostics market is expected to experience a growth spurt in the foreseeable future. Innovations in product design and technology have prompted doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines. The increased adoption of the personalized medicines approach would positively impact the DNA diagnostics market in the foreseeable future. Next generation sequencing is a powerful tool for decoding a number of human diseases, including various forms of cancer. Next generation sequencing reduces the cost of sequencing and increases the throughput. The optimization of sequencing technology could greatly impact the DNA diagnostics market.

The report breaks the market into segments based on product type, technology, application, end users and geography. Based on product types, the market is segmented into instruments, reagents and service & software. The instruments segment holds the dominant share in the market, due to improved healthcare facilities, availability of user-friendly instruments, its competitive cost structure, reliability, size and the growing demand for it in the DNA diagnostics market. However, the service & software segment is expected to grow at a steady rate in the near future due to technological advancements and the incorporation of information technology in the DNA diagnostics market. There are several technologies used in the DNA diagnostics market; these include PCR, mass spectrometry, sequencing technology, in-situ hybridization and microarrays. PCR holds the dominant share due to its frequent usage in diagnostic procedures such as sample preparation, separation and isolation of DNA from collected samples. The DNA diagnostics market is also segmented based on its application in various diseases such as oncology, infectious diseases and myogenic disorders. The oncology segment leads the market and is followed by infectious diseases due to the rising incidence of these diseases and growing elderly population. In terms of geography, the market is segmented into North America, Asia Pacific, Europe and LAMEA. North America holds the dominant share in the market due to the increased adoption of the DNA diagnostics technology and the high prevalence of chronic and infectious diseases. Companies profiled in the report include Roche Diagnostics, Bayer Diagnostic, Sysmex, Abbott laboratories, Gene-probe Inc., Cephide, Illumina, Inc., Bio-Rad Laboratories, Thermo Fisher Scientific, Johnson and Johnson, and Novartis.

KEY BENEFITS

- An in-depth analysis of various regions would provide a clear understanding of current and future trends so that companies can make region specific plans
- The report studies the application of next generation sequencing technology and biotechnology and their impact on the DNA diagnostics market
- A comprehensive analysis of the factors that drive and restrict the growth of the DNA diagnostics market is provided
- Key regulatory guidelines in various regions which impact the DNA diagnostics market are critically examined
- A quantitative analysis of the current market and estimations through 2013-2020 are provided to showcase the financial caliber of the DNA diagnostics market
- Detailed analysis of the Asia-pacific region provides insights that would enable companies to plan their business move strategically
- Value chain analysis in the report gives a clear understanding of the roles of the stakeholders involved in the supply chain of the DNA diagnostics market

MARKET SEGMENTATION:

The DNA diagnostics market is segmented based on product type, technology, application, end users and geography

MARKET BY PRODUCT TYPE

Instruments
Reagents
Service & Software

MARKET BY TECHNOLOGY

PCR
Microarray
In-situ Hybridization
Sequencing Technology
Mass Spectrometry
Others

MARKET BY APPLICATION

Oncology
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Others
Infectious Disease
- Hepatitis B Virus
- Hepatitis C Virus
- HIV
- TB
- Chlamydia Trachomatic and Neisseria Gonorrhea (CT/NG)
- HPV
- Methiciline Resistant Staphylococcus Aureus (MRSA)
- Others
Myogenic Disorder
Clinical Diagnostic Confirmation
Prenatal Diagnostics
Pre-implantation Diagnostics
Others

MARKET BY END USERS

Point of Care
Diagnostic Center
Self Testing/OTC

MARKET BY GEOGRAPHY

North America
Asia Pacific
Europe
LAMEA
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott laboratories
  • Bayer Diagnostic
  • Bio-Rad Laboratories
  • Cephide
  • Gene-probe Inc.
  • Illumina
  • MORE
CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Reason for doing the study

1.2.1 Key Benefits
1.2.2 Key Market Segments
1.2.3 Key Audiences

1.3 Research Methodology

1.3.1 Secondary Research
1.3.2 Primary Research
1.3.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO perspective
2.2 Market beyond what to expect by 2025 ($Million)

2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Application of biotechnology in DNA Diagnostic
3.3 Responsibility of Next-generation Sequencing technologies
3.4 Key Findings

3.4.1 Top Factors Impacting on DNA Diagnostics market
3.4.2 Top Investment Pockets of DNA Diagnostics market
3.4.3 Top winning strategies of DNA Diagnostics market

3.5 Government Regulations

3.5.1 FDA guidelines for personalized medicines

3.6 P orter’s Five force Analysis

3.6.1 Bargaining power of suppliers
3.6.2 Bargaining power of Buyers
3.6.3 Threat from new entrants
3.6.4 Threat of Substitute
3.6.5 Competitive Rivalry

3.7 Value chain analysis

3.7.1 Primary Activities
3.7.2 Supportive activities

3.8 Clinical Trials
3.9 Patent Analysis

3.9.1 Patent analysis by geographies(2010-2014)
3.9.2 Patent analysis by sub-segment (2010-2014)

3.10 Market Share Analysis,2013
3.11 Market Dynamics

3.11.1 Drivers

3.11.1.1 Increasing incidences of chronic and infectious diseases
3.11.1.2 Technological Advancements and product modification
3.11.1.3 Increase in popularity personalized medicine approach

3.11.2 Restraints

3.11.2.1 High cost involved in reaseach & development
3.11.2.2 Unclear reimbursement policies&stringent government regulation

3.11.3 Opportunities

3.11.3.1 Technological Development
3.11.3.2 Increasing need of Personalized Medicines

CHAPTER 4 GLOBAL DNA DIAGNOSTICS MARKET BY PRODUCT TYPES

4.1 Instruments

4.1.1 Key market trends
4.1.2 Competitive Scenario
4.1.3 Key growth factors and opportunities
4.1.4 Market size and forecast

4.2 Reagents

4.2.1 Key market trends
4.2.2 Competitive Scenario
4.2.1 Key growth factors and opportunities
4.2.2 Market size and forecast

4.3 Software & Services

4.3.1 Key market trends
4.3.1 Competitive Scenario
4.3.1 Key growth factors and opportunities
4.3.2 Market size and forecast

CHAPTER 5 GLOBAL DNA DIAGNOSTICS MARKET BY TECHNOLOGY, 2013-2020

5.1 PCR

5.1.1 Key market trends
5.1.2 Competitive scenario
5.1.3 Key growth factors and opportunities
5.1.4 Market size and forecast

5.2 Microarrays

5.2.1 Lab on chip
5.2.2 DNA microarray
5.2.3 Protein microarray
5.2.4 Key market trends
5.2.5 Competitive scenario
5.2.6 Key growth factors and opportunities
5.2.7 Market size and forecast

5.3 In situ hybridization

5.3.1 Key market trends
5.3.2 Competitive scenario
5.3.3 Key growth factors and opportunities
5.3.4 Market size and forecast

5.4 Sequencing Technology

5.4.1 Key market trends
5.4.2 Competitive scenario
5.4.3 Key growth factors and opportunities
5.4.4 Market size and forecast

5.5 Mass Spectrometry

5.5.1 Key market trends
5.5.2 Competitive scenario
5.5.3 Key growth factors and opportunities
5.5.4 Market size and forecast

5.6 Others

5.6.1 Key market trends
5.6.2 Competitive scenario
5.6.3 Key growth factors and opportunities
5.6.4 Market size and forecast

CHAPTER 6 GLOBAL DNA DIAGNOSTICS MARKET BY APPLICATIONS, 2013-2020

6.1 Oncology

6.1.1 Prostate Cancer
6.1.2 Breast Cancer
6.1.3 Colorectal Cancer
6.1.4 Others

6.2 Infectious disease testing

6.2.1 Hepatitis B Virus (HBV)
6.2.2 Hepatitis C Virus (HCV)
6.2.3 Human Immunodeficiency Virus (HIV)
6.2.4 Tuberculosis (TB)
6.2.5 Chlamydia Trachomatis and Neisseria Gonorrhoeae (CT/NG)
6.2.6 Human Papillomavirus (HPV)
6.2.7 Methicillin-Resistant Staphylococcus Aureus (MRSA)
6.2.8 Others

6.3 Myogenic disorder diagnosis
6.4 Clinical diagnosis confirmation
6.5 Prenatal diagnosis
6.6 Pre-implantation diagnosis
6.7 Others

CHAPTER 7 GLOBAL DNA DIAGNOSTIC MARKET BY END-USERS, 2013-2020

7.1 Point of Care
7.2 Central Laboratories/Diagnostic Centers
7.3 Self Testing/OTC

CHAPTER 8 GLOBAL DNA DIAGNOSTIC MARKET BY GEOGRAPHY, 2013-2020

8.1 North America

8.1.1 Key market trends
8.1.2 Competitive scenario
8.1.3 Key growth factors and opportunities
8.1.4 Market size and forecast
8.1.5 United States
8.1.6 Canada
8.1.7 Mexico

8.2 Europe

8.2.1 Key market trends
8.2.2 Competitive scenario
8.2.3 Key growth factors and opportunities
8.2.4 Market size and forecast
8.2.5 France
8.2.6 Germany
8.2.7 United Kingdom
8.2.8 Others

8.3 Asia-Pacific

8.3.1 Key market trends
8.3.2 Competitive scenario
8.3.3 Key growth factors and opportunities
8.3.4 Market size and forecast

8.4 LAMEA

8.4.1 Key market trends
8.4.2 Competitive scenario
8.4.3 Key growth factors and opportunities
8.4.4 Market size and forecast
8.4.5 Latin America
8.4.6 Middle East
8.4.7 Africa

CHAPTER 9 ASIA PACIFIC DNA DIAGNOSTIC MARKET ANALYSIS 2013-2020

9.1 Market dynamics
9.2 Key market trends
9.3 Clinical trials
9.4 Government regulations
9.5 Company analysis by region

9.5.1 India

9.5.1.1 Genome Diagnostics Pvt. Ltd.
9.5.1.2 Transasia
9.5.1.3 Dr Reddy’s lab

9.5.2 china
9.5.3 Australia

9.5.3.1 Genera biosystems

9.5.4 Japan

9.5.4.1 Sysmex

CHAPTER 10 COMPANY PROFILES

10.1 Sysmex

10.1.1 Company Overview
10.1.2 Company Snapshot
10.1.3 Financial performance
10.1.4 Strategic moves and developments

10.1.4.1 Primary Strategy: product launch
10.1.4.2 secondary Strategy: collaboration and partnership

10.1.5 SWOT analysis

10.2 Bayer Diagnostic

10.2.1 Overview
10.2.2 Company snapshot
10.2.3 Financial performance
10.2.4 Strategic moves and developments

10.2.4.1 Primary Strategy: product launch

10.2.5 SWOT analysis

10.3 Roche Diagnostics

10.3.1 Overview
10.3.2 Company snapshot
10.3.3 Financial performance
10.3.4 Strategic moves and developments

10.3.4.1 Primary Strategies:product launch
10.3.4.2 Secondary Strategy: Collaboration

10.3.5 SWOT analysis

10.4 Abbott Laboratories

10.4.1 Overview
10.4.2 Company snapshot
10.4.3 Financial performance
10.4.4 Strategic moves and developments

10.4.4.1 Primary Strategies: product launch

10.4.5 SWOT analysis

10.5 Cephide Inc.

10.5.1 Overview
10.5.2 Company snapshot
10.5.3 Financial performance
10.5.4 Strategic moves and developments

10.5.4.1 Primary Strategies: partnership and product launch
10.5.4.2 Secondary Strategy: Collaboration

10.5.5 SWOT analysis

10.6 Gen-probe Inc. (Hologic)

10.6.1 Overview
10.6.2 Company snapshot
10.6.3 Financial performance
10.6.4 Strategic moves and developments

10.6.4.1 Primary Strategy: product launch

10.6.5 SWOT analysis

10.7 Illumina, Inc.

10.7.1 Overview
10.7.2 Company snapshot
10.7.3 Financial performance
10.7.4 Strategic moves and developments

10.7.4.1 Primary Strategies: partnership and product launch

10.7.5 SWOT analysis

10.8 Thermo Fisher Scientific

10.8.1 Overview
10.8.2 Company snapshot
10.8.3 Financial performance
10.8.4 Strategic moves and developments

10.8.4.1 Primary Strategies:product launch
10.8.4.2 Secondary Strategy: Collaborationand acquisition

10.8.5 SWOT analysis

10.9 Bio-Rad Laboratories

10.9.1 Overview
10.9.2 Company snapshot
10.9.3 Financial performance
10.9.4 Strategic moves and developments

10.9.4.1 Primary Strategies: product launch
10.9.4.2 Secondary Strategies: Acquistaion

10.9.5 SWOT analysis

10.10 Johnson and Johnson

10.10.1 Overview
10.10.2 Company snapshot
10.10.3 Financial performance
10.10.4 Strategic moves and developments

10.10.4.1 Primary strategies: collaboration

10.10.5 SWOT analysis

10.11 Novartis

10.11.1 Overview
10.11.2 Company snapshot
10.11.3 Financial performance
10.11.4 Strategic moves and developments

10.11.4.1 Primary Strategies: product launch
10.11.4.2 secondary Strategies: collaboration and partnership

10.11.5 SWOT analysis

List of Tables
TABLE 1 Dna diagnostic market moderate growth scenario by geography, 2020-2025 ($Million)
TABLE 2 Dna diagnostic market rapid growth scenario by geography, 2020-2025 ($Million)
TABLE 3 Dna diagnostic market diminishing growth scenario by geography, 2020-2025 ($Million)
TABLE 4 Milestone of FDA guidelines for personalized medicines
TABLE 5 Clinical trials conducted for DNA diagnostics technologies
TABLE 6 Chronic Disease Prevalence
TABLE 7 Types of DNA diagnostic devices by technology
TABLE 8 Global dna diagnostic market revenue by product types, 2013-2020 ($Million)
TABLE 9 Global Instrument dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 10 Global reagents dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 11 Global software & services dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 12 Global dna diagnostic market revenue by technology 2013-2020 ($Million)
TABLE 13 Global PCR technology market revenue by geography: 2020-2025 ($Million)
TABLE 14 Microarray technology pricing chart
TABLE 15 Global Microarray technology market revenue by geography, 2013-2020 ($Million)
TABLE 16 In situ hybridization devices pricing chart
TABLE 17 Global In situ hybridization technology market revenue by geography, 2013-2020 ($Million)
TABLE 18 Global sequencing technology market revenue by market revenue by geography, 2013-2020 ($Million)
TABLE 19 laboratory equipment prices
TABLE 20 Global mass spectrometry market revenue by geography, 2013-2020 ($Million)
TABLE 21 Global other technology market revenue by geography, 2013-2020 ($Million)
TABLE 22 Global dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 23 Global oncology dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 24 Global Infectious diseases dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 25 Global Myogenic disorder dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 26 Global Clinical dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 27 Global Prenatal dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 28 Global Per-implantation dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 29 Other dna diagnostic application market revenue by geography, 2013-2020 ($Million)
TABLE 30 Global dna diagnostic market revenue by end users: 2013-2020 ($Million)
TABLE 31 Global point of care dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 32 Global diagnostic center dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 33 Global Self testing/OTC dna diagnostic market revenue by geography, 2013-2020 ($Million)
TABLE 34 United states dna diagnostics market revenue by application, 2013-2020 ($ million)
TABLE 35 Canada dna diagnostic market revenue by application, 2013-2020 ($ million)
TABLE 36 Mexico dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 37 France dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 38 Germany dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 39 United kingdom dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 40 Others dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 41 Asia pacific dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 42 lamea dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 43 LAtin america dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 44 Middle east dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 45 Africa dna diagnostic market revenue by application, 2013-2020 ($Million)
TABLE 46 Company snapshot of Sysmex
TABLE 47 Company snapshot of Bayer Diagnostic
TABLE 48 Company snapshot of Roche DIAGNOSTICS
TABLE 49 Company snapshot of Abbott Laboratories
TABLE 50 Company snapshot Cephide inc
TABLE 51 Company snapshot of Gen-probe Inc. (Hologic)
TABLE 52 Company snapshot of Illumina, Inc.
TABLE 53 Company snapshot of Thermo Fisher Scientific
TABLE 54 Company snapshot of Bio-Rad Laboratories
TABLE 55 Company snapshot of Johnson & Johnson
TABLE 56 Company snapshot of Novartis

List of Figures
FIG.1 Top Factors Impacting on DNA Diagnostics market
FIG.2 Top Investment Pockets of DNA Diagnostics market
FIG.3 Top winning strategies for DNA diagnostic market during 2010-2014
FIG.4 Recent development of DNA diagnostic market by companies (2010-2014)
FIG.5 Top wining strategies by subtype of developments
FIG.6 Porter’s Five force Analysis of DNA DIagnostics market
FIG.7 Value chain analysis of Dna diagnostics market
FIG.8 Patent analysis by geographies (2010-2014)
FIG.9 Patent analysis of Sub Segment(2010-2014)
FIG.10 Market share analysis of DNA diagnostics market
FIG.11 Factors affecting the commercial potential of companies developing a molecular diagnostic
FIG.12 Net sales by geographic region (2013)
FIG.13 SWOT analysis of sysmex
FIG.14 Revenue generated
FIG.15 Revenue generation by segments
FIG.16 Swot analysis of Bayer
FIG.17 Net diagnostic sales by geography (2013)
FIG.18 SWOT analysis of roche Diagnostics
FIG.19 Net revenue generation by abbott (2012-2013)
FIG.20 Net revenue generation by segments (2013)
FIG.21 SWOT analysis of abbott LABORATORIES
FIG.22 Net sales by geography (2013)
FIG.23 Net sales by clinical and non clinical market(2013)
FIG.24 SWOT analysis of cepheid inc.
FIG.25 Revenue generated by the company in 2011 and 2012
FIG.26 SWOT analysis of Gen-probe Inc. (Hologic)
FIG.27 Net revenue generation (2012-2013)
FIG.28 SWOT analysis of ILLUMINA, INC.
FIG.29 Net sales by segments (2013)
FIG.30 Revenue generation (2011-2013)
FIG.31 Revenue genetaration by segments (2013)
FIG.32 Swot analysis of Thermo Fisher Scientific
FIG.33 Net revenue generation (2011-2013)
FIG.34 Net sales by segments (2013)
FIG.35 Net sales by geogrephy (2013)
FIG.36 SWOT analysis of bio-rad laboratories
FIG.37 Revenue generation by Segment (2013)
FIG.38 Revenues generation by Geography (2013)
FIG.39 SWOT analysis of johnson & johnson
FIG.40 Net revenue generation by geography (2013)
FIG.41 Net revenue generation by businesses (2013)
FIG.42 SWOT analysis of Novartis
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbott laboratories
  • Bayer Diagnostic
  • Bio-Rad Laboratories
  • Cephide
  • Gene-probe Inc.
  • Illumina
  • MORE
This new report titled, "DNA diagnostics Market (products, applications, techniques, end users and Geography) Global Size, Industry Analysis, Trends, Opportunities, Growth and Forecast, 2013 - 2020," indicates that the global DNA diagnostics market would reach $19 billion by 2020 registering a CAGR of 9.8% from 2014 to 2020. The potential to provide accurate diagnosis and cost effectiveness over alternative diagnostic techniques are factors which supplement the growth of the DNA diagnostics market.AMR analysis suggests that the tremendous potential of novel DNA diagnostic technologies and the probability of them being adopted in personalized medicines has not only reduced the expenditure in diagnostic procedures but has also helped in increasing the efficiency of chronic disease identification. Furthermore, the emergence of personalized medicines and the rising number of initiatives vis-à-vis product development and clinical trials from key players has laid the groundwork for DNA diagnostics technologies. Various technologies such as PCR, sequencing technology, microarray, in situ hybridization and mass spectrometry are considered in this report, with special emphasis on key market trends and their growth potential. Given its wide scope of application in almost all activities related to DNA diagnostics, the polymerase chain reaction (PCR) technology holds the largest share of DNA diagnostics market revenue.

Market analysis in terms of geography suggests that developed economies would retain their dominance in the market. This could be attributed to the early adoption of the technology due to potential reduction offered by DNA diagnostic to their high healthcare expenditure. However, developing economies, such as in Asia-Pacific, will significantly influence the DNA diagnostic market during the extended forecast period (2020-2025), largely due to potential growth in per capita healthcare expenditure and very large undiagnosed population.

Several companies operating in this region are seeking novel technologies to gain traction in the competitive market. Product launch is the key strategy adopted by companies operating in this market. These companies are developing novel products for the treatment of various diseases such as infectious diseases, cancer, prenantal diagnosis, pre-implantation diagnostics and myogenic disorder. Additionally, these companies are also adopting collaboration and acquisition to retain their respective positions and to gain traction in the market. Key companies profiled in the report are Bayer Diagnostic, Sysmex, Roche Diagnostics, Abbott laboratories, Cephide, Gene-probe Inc., Illumina, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Johnson and Johnson, and Novartis.

The latest figures suggest that approximately 8.2 million people are living with cancer and 39 million with HIV. These numbers are set to increase consistently; however, advanced automated DNA diagnostics technologies such as next generation sequencing could play a crucial role in diagnosing and curbing these diseases. "Next generation sequencing has had a significant impact on diagnostic procedures and is set to gain momentum in the foreseeable future.", states AMR analyst Sharayu Dhabale. "Next generation sequencing not only reduces the cost of sequencing, but increases the throughput as well; it could thus help in bridging the gaps in traditional and personalized medications", adds the analyst. This makes it a promising investment opportunity for key players. Illumina Inc's new cost-effective genome machine HiSeq X Ten -the world's first DNA crunching supercomputer- is leading to a significant reduction in the price of sequencing a human genome.
Note: Product cover images may vary from those shown
5 of 5
- Abbott laboratories
- Bayer Diagnostic
- Bio-Rad Laboratories
- Cephide
- Gene-probe Inc.
- Illumina
- Johnson and Johnson
- Novartis
- Roche Diagnostics
- Sysmex
- Thermo Fisher Scientific

Note: Product cover images may vary from those shown
6 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll